CN112703012A - 治疗癌症的方法 - Google Patents

治疗癌症的方法 Download PDF

Info

Publication number
CN112703012A
CN112703012A CN201980047070.3A CN201980047070A CN112703012A CN 112703012 A CN112703012 A CN 112703012A CN 201980047070 A CN201980047070 A CN 201980047070A CN 112703012 A CN112703012 A CN 112703012A
Authority
CN
China
Prior art keywords
icos
cancer therapies
agonist
antibody
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980047070.3A
Other languages
English (en)
Chinese (zh)
Inventor
C·哈维
D·劳
A·E·汉森
M·Y·范
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vibration Therapy Co
Original Assignee
Vibration Therapy Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vibration Therapy Co filed Critical Vibration Therapy Co
Publication of CN112703012A publication Critical patent/CN112703012A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980047070.3A 2018-05-14 2019-05-14 治疗癌症的方法 Pending CN112703012A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862671181P 2018-05-14 2018-05-14
US62/671181 2018-05-14
US201862679346P 2018-06-01 2018-06-01
US62/679346 2018-06-01
US201862750026P 2018-10-24 2018-10-24
US62/750026 2018-10-24
US201962827312P 2019-04-01 2019-04-01
US62/827312 2019-04-01
PCT/US2019/032184 WO2019222188A1 (en) 2018-05-14 2019-05-14 Methods of treating cancer

Publications (1)

Publication Number Publication Date
CN112703012A true CN112703012A (zh) 2021-04-23

Family

ID=66690990

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980047070.3A Pending CN112703012A (zh) 2018-05-14 2019-05-14 治疗癌症的方法

Country Status (5)

Country Link
US (2) US11292840B2 (https=)
EP (1) EP3793598A1 (https=)
JP (1) JP2021523213A (https=)
CN (1) CN112703012A (https=)
WO (1) WO2019222188A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112807425A (zh) * 2021-01-14 2021-05-18 南方医科大学深圳医院 一种tTIM融合蛋白疫苗、制备方法及应用
CN118516308A (zh) * 2024-07-22 2024-08-20 深圳市中佳生物医疗科技有限公司 免疫调节剂在制备增强nk细胞毒性作用的产品中的应用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
CA2890346A1 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
EP2945652B1 (en) 2013-01-18 2021-07-07 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US20200024351A1 (en) * 2017-04-03 2020-01-23 Jounce Therapeutics, Inc. Compositions and Methods for the Treatment of Cancer
EP3870610A1 (en) * 2018-10-24 2021-09-01 Jounce Therapeutics, Inc. Methods and compositions for the treatment of cancer and infectious diseases
EP4058593A4 (en) 2019-11-12 2023-11-15 Foundation Medicine, Inc. METHODS FOR DETECTING A FUSION GENE ENCODING A NEO-ANTIGEN
JP2023510847A (ja) * 2020-01-13 2023-03-15 ジャウンス セラピューティックス， インク． 癌の治療方法
AU2021260553A1 (en) * 2020-04-20 2022-10-20 Jounce Therapeutics, Inc. Compositions and methods for vaccination and the treatment of infectious diseases
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
US20220396623A1 (en) 2021-05-18 2022-12-15 Kymab Limited Uses of anti-icos antibodies
WO2022272309A1 (en) 2021-06-25 2022-12-29 Foundation Medicine, Inc. Methods of using somatic hla-i loh to predict response of immune checkpoint inhibitor-treated patients with lung cancer
US20250340641A1 (en) 2022-05-18 2025-11-06 Kymab Limited Uses of anti-icos antibodies
JP2025160816A (ja) * 2024-04-10 2025-10-23 イミューンオンコ バイオファーマシューティカルズ （シャンハイ） インコーポレイテッド 古典的ホジキンリンパ腫に対する併用療法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070423A1 (en) * 2015-10-22 2017-04-27 Jounce Therapeutics, Inc. Gene signatures for determining icos expression
CN107530428A (zh) * 2015-03-23 2018-01-02 震动疗法股份有限公司 Icos的抗体
CA3032897A1 (en) * 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
WO2018029474A2 (en) * 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
ES2612914T3 (es) 2011-03-31 2017-05-19 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos dirigidos contra Icos y usos de los mismos
CA2889182A1 (en) 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
SG11201506920QA (en) 2013-03-15 2015-09-29 Bristol Myers Squibb Co Ido inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107530428A (zh) * 2015-03-23 2018-01-02 震动疗法股份有限公司 Icos的抗体
WO2017070423A1 (en) * 2015-10-22 2017-04-27 Jounce Therapeutics, Inc. Gene signatures for determining icos expression
CA3032897A1 (en) * 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
WO2018029474A2 (en) * 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HONG CHEN等: "CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy", CANCER IMMUNOL RES, vol. 2, no. 2, 19 November 2013 (2013-11-19) *
JENNIFER S.MICHAELSON等: "Abstract SY03-02_ Preclinical assessment of JTX-2011, an agonist antibody targeting ICOS, supports evaluation in ICONIC clinical trial", IMMUNOLOGY, 1 July 2017 (2017-07-01), pages 03 - 02 *
JULIEN FAGET等: "ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4+ T cells by plasmacytoid dendritic cells", ONCOLMMUNOLOGY, vol. 2, no. 3, 1 March 2013 (2013-03-01), pages 23185, XP055328805, DOI: 10.4161/onci.23185 *
KINGA MAJCHRZAK等: "Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic", CANCER IMMUNOL IMMUNOTHER, vol. 65, no. 3, 29 January 2016 (2016-01-29), pages 247 - 259, XP035871381, DOI: 10.1007/s00262-016-1797-6 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112807425A (zh) * 2021-01-14 2021-05-18 南方医科大学深圳医院 一种tTIM融合蛋白疫苗、制备方法及应用
CN118516308A (zh) * 2024-07-22 2024-08-20 深圳市中佳生物医疗科技有限公司 免疫调节剂在制备增强nk细胞毒性作用的产品中的应用
CN118516308B (zh) * 2024-07-22 2024-10-22 深圳市中佳生物医疗科技有限公司 免疫调节剂在制备增强nk细胞毒性作用的产品中的应用

Also Published As

Publication number Publication date
US20190367613A1 (en) 2019-12-05
US11292840B2 (en) 2022-04-05
WO2019222188A1 (en) 2019-11-21
EP3793598A1 (en) 2021-03-24
JP2021523213A (ja) 2021-09-02
US20220332823A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
US20220332823A1 (en) Methods of treating cancer
TWI719970B (zh) 針對ｉｃｏｓ之抗體
HK1258249A1 (zh) 用於测定icos表达的基因标志
EP3938396A1 (en) Anti-icos antibodies for the treatment of cancer
US20240199732A1 (en) Anti-IL-27 Antibodies and Uses Thereof
CA3093740A1 (en) Anti-il-27 antibodies and uses thereof
KR20220007087A (ko) 제한된 수의 nk 세포를 갖는 환자에서의 항-cd19 치료제
US20210353750A1 (en) Methods of Treating Cancer
US10746726B2 (en) Method for assessing therapeutic effect of anti-cancer agent having anti-CD4 antibody as active ingredient
US20210355222A1 (en) Methods of Treating Cancer
US20210380942A1 (en) Methods and compositions for the treatment of cancer and infectious diseases
US20230089426A1 (en) Methods for the treatment of cancer
RU2820275C2 (ru) Антитела, специфичные в отношении нектина-2 человека
WO2025175166A1 (en) Combination therapies with btn1a1 binding proteins and chemotherapeutic agents
WO2026052650A1 (en) Use of fap-cd40 bispecific antibody for the modulation of the tumor microenvironment
HK40110611A (zh) 癌症的组合治疗中针对cd40和cd137的多特异性结合剂
HK1254148A1 (en) Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
HK1248127B (en) Antibodies to icos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210423

WD01 Invention patent application deemed withdrawn after publication